New indication criteria: better availability of GLP1 receptor agonists for our patients
Authors:
Zbynek Schroner
Authors‘ workplace:
Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in:
Diab Obez 2023; 23(45): 61-62
Category:
News
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2023 Issue 45
Most read in this issue
- The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus
- Evaluation of the current situation and possibilities in the management of obesity in Slovakia
- Practical experience with dapagliflozin: case reports
- Diabetes mellitus and options for early prevention of heart failure